Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This study found that VYC-15L (Juvéderm Volbella XC) was safe and effective for enhancing lip and perioral areas, achieving higher lip fullness improvement and fewer severe injection site reactions compared to NASHA, with effects lasting up to one year.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

This study found that Juvéderm Ultra Plus was safe and effective for correcting severe nasolabial folds in a Chinese population, requiring less volume than Restylane while achieving similar responder rates, with fewer severe treatment site reactions.

In this study of 35 patients with scalp alopecia areata, calcipotriol ointment led to faster and greater hair regrowth than clobetasol, though differences were not statistically significant.

This study found that mupirocin nanoparticle-loaded hydrogel was safe and more effective for healing burn wounds in rats compared to mupirocin ointment, showing promise for future clinical trials.

This review summarizes existing literature on the safety of commonly used dermatologic medications during pregnancy but does not present new clinical findings, aiming to assist physicians with prescribing decisions.

In this study, Trf1 genetic deletion in mice, including those with cancer-prone mutations, was shown to not affect overall viability and cause only mild effects, while being necessary for tumor formation, suggesting a potential therapeutic window for Trf1 as an anti-cancer target.

This study found that treating asymptomatic or mild COVID-19 with cepharanthine did not significantly reduce the time to a negative test result, though 60 mg/day showed a non-significant trend needing further validation.

This study found that dutasteride was more effective than finasteride in increasing total and thick hair count and reducing thin hair count in men with AGA, with both drugs having similar side effect profiles.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

In this study, 60 mg/day of Cepharanthine significantly reduced the time to a negative COVID-19 test among de novo infected patients with good compliance, though 120 mg/day showed no such effect.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.

This Delphi consensus study provides expert insights into hair aging, aims to enhance diagnostic precision and management of age-related hair changes, and identifies possible new therapeutic targets.

This review concluded that LED-based photobiomodulation is generally safe and effective for certain dermatologic conditions, though consumer devices often show less efficacy compared to professional systems.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

In this randomized, placebo-controlled study, Kūlaris supplementation significantly improved quality of life for participants with mild-to-severe acne over 12 weeks, though no significant changes in general skin health measures were observed compared to placebo.

This review discusses the use of platelet-rich plasma for treating female androgenetic alopecia, reporting that it shows high patient satisfaction and improved quality of life in affected women.

This study found that adding cyclophosphamide to glucocorticoid treatment for pemphigus patients led to earlier remission, with 89.5% achieving remission within 4 months compared to 73.9% with glucocorticoids alone, suggesting significant steroid-sparing effects and improved clinical outcomes.

Acne and hair loss are not good indicators of hormone imbalance in PCOS, but excessive body hair is.

In this randomized, double-blind trial, researchers observed that low-level laser therapy led to significantly greater hair regrowth on treated areas compared to a sham treatment in patients with androgenetic alopecia over 24 weeks, suggesting it as a potentially effective and safe option.

This chapter reviews nanotechnology in cosmetics, detailing various formulations, performance assessment methods, and evolving regulations, while discussing safety, stability, and effectiveness concerns; it reports no new experimental results.

In this randomized trial, bimatoprost 0.01% significantly improved eyebrow hair density and diameter in patients with eyebrow hypotrichosis compared to a placebo, with minimal adverse effects, suggesting it is an effective and safe treatment option.

This study found that both 0.01% and 0.03% bimatoprost gel and 2% minoxidil gel significantly improved eyebrow density in individuals with hypotrichosis, with no significant difference between the treatments, although the highest bimatoprost concentration showed a more favorable response.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study found that platelet-rich plasma therapy was more effective in increasing hair count than topical 5% minoxidil lotion in men with androgenetic alopecia.